EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Enhancement of CAR‐T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins

Yidan Qiao iD, Jie Chen, Xuemei Wang, Shumei Yan, Jizhou Tan, Baijin Xia, Yongjian Chen, Keming Lin, Fan Zou, Bingfeng Liu, Xin He iD, Yiwen Zhang und 4 weitere

Cancer Communications · 2023-07 · 43 (7) · 788-807

DOI: 10.1002/cac2.12452 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Communications, online erschienen am 06.06.2023. Verfasst von Yidan Qiao und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Guangzhou Science and Technology Innovation development Special fund, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Existing treatments for cholangiocarcinoma have poor efficacy. However, chimeric antigen receptor‐T (CAR‐T) cells are emerging as a potential therapeutic strategy. Solid tumors possess multiple adverse factors in an immunosuppressive microenvironment that impair CAR‐T cell infiltration and function. This study aimed to improve the function of CAR‐T cells through knock down immune checkpoints and immunosuppressive molecular receptors.

Methods

We evaluated the expression of epidermal growth factor receptor (EGFR) and B7 homolog 3 protein (B7H3) antigens in cholangiocarcinoma tissues using immunohistochemistry and screened specific immune checkpoints in the cholangiocarcinoma microenvironment via flow cytometry. Subsequently, we engineered CAR‐T cells targeting EGFR and B7H3 antigens. We simultaneously knocked down immune checkpoints and immunosuppressive molecular receptors in CAR‐T cells by constructing two clusters of small hairpin RNAs and evaluated the engineered CAR‐T cells for antitumor activity both in vitro, using tumor cell lines and cholangiocarcinoma organoid models, and in vivo, using humanized mouse models.

Results

We observed high expression of EGFR and B7H3 antigens in cholangiocarcinoma tissues. EGFR‐CAR‐T and B7H3‐CAR‐T cells demonstrated specific anti‐tumor activity. We found an abundance of programmed cell death protein 1 (PD‐1), T cell immunoglobulin and mucin domain‐containing protein 3 (Tim‐3), and T cell immunoglobulin and ITIM domain (Tigit) on infiltrated CD8 + T cells in the cholangiocarcinoma microenvironment. We then decreased the expression of these 3 proteins on the surface of CAR‐T cells, named PTG‐scFV‐CAR‐T cells. Furthermore, we knocked‐down the expression of transforming growth factor beta receptor (TGFβR), interleukin‐10 receptor (IL‐10R), and interleukin‐6 receptor (IL‐6R) of PTG‐scFV‐CAR‐T cells. Those cells, named PTG‐T16R‐scFV‐CAR‐T cells, potently killed tumor cells in vitro and promoted apoptosis of tumor cells in a cholangiocarcinoma organoid model. Finally, the PTG‐T16R‐scFv‐CAR‐T cells showed greater inhibitory effect on tumor growth in vivo, and were superior in prolonging the survival of mice.

Conclusions

Our results revealed that PTG‐T16R‐scFV‐CAR‐T cells with knockdown of sextuplet inhibitory molecules exhibited strong immunity against cholangiocarcinoma and long‐term efficacy both in vitro and in vivo. This strategy provides an effective and personalized immune cell therapy against cholangiocarcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenCholangiocarcinomaBile Duct NeoplasmsAnimalsMiceCD8-Positive T-LymphocytesMembrane ProteinsXenograft Model Antitumor AssaysErbB ReceptorsImmunosuppressive AgentsBile Ducts, IntrahepaticImmunoglobulinsTumor Microenvironment

Stichwörter der Autor:innen

CAR-TT cell receptorcholangiocarcinomaimmunosuppressionliver cancertumor microenvironment

Substanzen

Receptors, Chimeric AntigenMembrane ProteinsErbB ReceptorsImmunosuppressive AgentsImmunoglobulins

Autor:innen und Institutionen

  • Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.
  • Key Laboratory of Tropical Disease Control of Ministry Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Institute of Human Virology, Sun Yat-sen University, Guangzhou, Guang…
  • Guangzhou National Laboratory, Bio-Island, Guangzhou, Guangdong, P. R. China.

ORCID-Profile: Yidan Qiao, Xin He

Förderung

  • Guangzhou Science and Technology Innovation development Special fund
  • National Natural Science Foundation of China

Zitieren

APA

Qiao, Y., Chen, J., Wang, X., Yan, S., Tan, J., Xia, B., Chen, Y., Lin, K., Zou, F., Liu, B., He, X., Zhang, Y., Zhang, X., Zhang, H., Wu, X., & Lu, L. (2023). Enhancement of CAR‐T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins. Cancer Communications, 43(7), 788-807. https://doi.org/10.1002/cac2.12452

Vancouver

Qiao Y, Chen J, Wang X, Yan S, Tan J, Xia B, et al. Enhancement of CAR‐T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins. Cancer Communications. 2023;43(7):788-807. doi:10.1002/cac2.12452

BibTeX
@article{Qiao2023,
  author = {Qiao, Yidan and Chen, Jie and Wang, Xuemei and Yan, Shumei and Tan, Jizhou and Xia, Baijin and Chen, Yongjian and Lin, Keming and Zou, Fan and Liu, Bingfeng and He, Xin and Zhang, Yiwen and Zhang, Xu and Zhang, Hui and Wu, Xiangyuan and Lu, Lijuan},
  title = {Enhancement of CAR‐T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins},
  journal = {Cancer Communications},
  year = {2023},
  volume = {43},
  number = {7},
  pages = {788--807},
  doi = {10.1002/cac2.12452}
}
Kostenlos starten →